Literature DB >> 17448146

Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

Katerina K Papachroni1, Natalia Ninkina, Angeliki Papapanagiotou, Georgios M Hadjigeorgiou, Georgia Xiromerisiou, Alexandros Papadimitriou, Anastasios Kalofoutis, Vladimir L Buchman.   

Abstract

Neurodegeneration in Parkinson's disease (PD) is accompanied by a local immune reaction in the affected brain regions. It is well established that alpha-synuclein is directly implicated in the pathogenesis of PD. Development of the disease is often associated with changes of expression and cellular compartmentalisation of this protein; moreover, its oligomers or protofibrils are often released to the CSF and plasma of patients. Aggregated alpha-synuclein can trigger the activation of microglia; however, its capacity to induce production of specific autoantibodies (AAb) has not been assessed. In this study, we examined the presence of AAb against synuclein family members in the peripheral blood serum of PD patients and control individuals. Presence of AAb against beta-synuclein or gamma-synuclein showed no association with PD. Multi-epitopic AAb against alpha-synuclein were detected in 65% of all patients tested and their presence strongly correlated with an inherited mode of the disease but not with other disease-related factors. The frequency of the presence of AAb in the studied group of patients with sporadic form of PD was not significantly different from the frequency in the control group but very high proportion (90%) of patients with familial form of the disease were positive for AAb against alpha-synuclein. We hypothesise that these AAb could be involved in pathogenesis of the inherited form of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448146      PMCID: PMC3154646          DOI: 10.1111/j.1471-4159.2006.04365.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  29 in total

1.  Progress towards a vaccine for Huntington's disease.

Authors:  Ruth Luthi-Carter
Journal:  Mol Ther       Date:  2003-05       Impact factor: 11.454

Review 2.  The role of alpha-synuclein in Parkinson's disease: insights from animal models.

Authors:  Eleonora Maries; Biplob Dass; Timothy J Collier; Jeffrey H Kordower; Kathy Steece-Collier
Journal:  Nat Rev Neurosci       Date:  2003-09       Impact factor: 34.870

3.  Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.

Authors:  G Xiromerisiou; G M Hadjigeorgiou; V Gourbali; J Johnson; I Papakonstantinou; A Papadimitriou; A B Singleton
Journal:  Eur J Neurol       Date:  2007-01       Impact factor: 6.089

Review 4.  The role of costimulation in autoimmune demyelination.

Authors:  M K Racke; R B Ratts; L Arredondo; P J Perrin; A Lovett-Racke
Journal:  J Neuroimmunol       Date:  2000-07-24       Impact factor: 3.478

5.  Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.

Authors:  Mario Delgado; Doina Ganea
Journal:  FASEB J       Date:  2003-03-05       Impact factor: 5.191

6.  Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.

Authors:  J Bas; M Calopa; M Mestre; D G Molleví; B Cutillas; S Ambrosio; E Buendia
Journal:  J Neuroimmunol       Date:  2001-02-01       Impact factor: 3.478

7.  Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Eric J Benner; R Lee Mosley; Chris J Destache; Travis B Lewis; Vernice Jackson-Lewis; Santhi Gorantla; Craig Nemachek; Steven R Green; Serge Przedborski; Howard E Gendelman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

8.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

Authors:  Honglei Chen; Shumin M Zhang; Miguel A Hernán; Michael A Schwarzschild; Walter C Willett; Graham A Colditz; Frank E Speizer; Alberto Ascherio
Journal:  Arch Neurol       Date:  2003-08

Review 9.  Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections).

Authors:  Garth E Ringheim; Katherine Conant
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

10.  gamma delta+ T cells are increased in patients with Parkinson's disease.

Authors:  U Fiszer; E Mix; S Fredrikson; V Kostulas; T Olsson; H Link
Journal:  J Neurol Sci       Date:  1994-01       Impact factor: 3.181

View more
  75 in total

1.  Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Authors:  L M Patrias; A C Klaver; M P Coffey; D A Loeffler
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  [Innovative treatment approaches for Alzheimer's disease. Immunotherapy].

Authors:  R Dodel; M Bacher
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 4.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 5.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

Review 6.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 7.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

Review 8.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

9.  Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Authors:  Wenbin Xiao; Afshin Shameli; Clifford V Harding; Howard J Meyerson; Robert W Maitta
Journal:  Immunobiology       Date:  2014-07-22       Impact factor: 3.144

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.